bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion. The assay uses a unique combination of the biomarkers GFAP and UCH-L1*, proteins that enter circulation following cellular injury1. The test can help reduce the number of unnecessary head Computed Tomography (CT) scans performed for mTBI patients by predicting the absence of accute intracranial lesions (ICL).
Traumatic brain injury is defined as the transfer of external mechanical energy to brain tissue resulting in cellular damage, dysfunction, and dysregulation2. As a leading cause of death and disability, TBI is a major public health burden. About 69 million people suffer from it worldwide every year3. For the clinicians evaluating these patients, it is often imperative to determine the presence or absence of life-threatening hemorrhage and neurologic complications.
Based on clinical presentation and assessment of severity using the Glasgow Coma Scale (GCS), TBI is currently characterized as mild, moderate, or severe. Of these, mild traumatic brain injuries are the most prevalent, accounting for 70-90% of all TBI diagnoses4. Fortunately, they are the least likely to result in acute medical emergencies5. It is estimated that 90% of mTBI patients who undergo CT scans will be negative for abnormal findings. Despite this statistic, use of imaging remains common with an estimated 82% of all TBI patients receiving scans6. A significant number of these scans could be avoided given that they increase patient workup time, expose patients to CT-scan radiation and take up resources of burdened ED departments5.
A game changing test contributing to an efficient triage for mTBI’s
An easy-to-interpret test from the immunoassay range VIDAS®, VIDAS® TBI (GFAP, UCH-L1) measures the concentration of GFAP and UCH-L1, two brain biomarkers that are released into the bloodstream starting from the first hour following a brain injury. When used in conjunction with clinical information, VIDAS® TBI (GFAP, UCH-L1) results can aid clinicians in determining the need for CT imaging of the head in adult patients (18 years or older), presenting within a large testing window of up to 12 hours after injury, and help shorten ED workup time. A negative test result assists in determining the need for a CT-scan by predicting the absence of acute intracranial lesions7.
“Securing FDA clearance for the VIDAS® TBI (GFAP, UCH-L1), marks another significant milestone in our journey toward innovative solutions for our customers and improving patient outcomes,” said Colin Hill, General Manager and Head of Clinical Operations, North America. “This enables clinicians to confidently perform fast, efficient triage for mTBI’s, resulting in faster and more informed decisions for personalized treatment of patients.”
“In keeping with the legacy of bioMérieux, we remain committed to developing diagnostic solutions that will improve the delivery of healthcare, have a positive societal impact, and help make the world a healthier place,” said Dr. Charles K. Cooper, Executive Vice President and Chief Medical Officer. “In recognizing the enormity of traumatic brain injury, the VIDAS® TBI (GFAP, UCH-L1) assay contributes to the advancement of current practices in disease evaluation.”
VIDAS® TBI (GFAP, UCH-L1) is available on VIDAS® 3 and VIDAS® KUBE™ immunoanalyzers, offering on-demand automated testing 24/7. The assay’s commercial launch is planned for the second half of 2024 in the United States. VIDAS® TBI (GFAP, UCH-L1) is also CE-marked** and commercialized in selected European, North African and South American countries.
